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Abstract 
The incidence of drug-induced acute liver failure is increasing. A number of drugs can 
inhibit mitochondrial functions, alter β-oxidation and cause accumulation of free fatty 
acids within the hepatocytes. This may result in hepatic steatosis, cell death and liver 
injury. In our case, propofol, an anesthetic drug commonly used in adults and children, is 
suspected to have induced disturbance of the mitochondrial respiratory chain, which in 
consequence led to insufficient energy supply and finally liver failure. We report the case 
of a 35-year-old Caucasian woman with acute liver failure after anesthesia for stripping of 
varicose veins. Liver histology, imaging and laboratory data indicate drug-induced acute 
liver failure, presumably due to propofol. Hepatocyte death and microvesicular fatty 
degeneration of 90% of the liver parenchyma were observed before treatment with 
steroids. Six months later, a second biopsy was performed, which revealed only minimal 
steatosis and minimal periportal hepatitis. We suggest that propofol led to impaired fatty 
acid oxidation possibly due to a genetic susceptibility. This caused free fatty acid 
accumulation within hepatocytes, which presented as hepatocellular fatty degeneration 
and cell death. Large scale hepatocyte death was followed by impaired liver function 
and, consecutively, progressed to acute liver failure. 
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Introduction 
As the incidence of acute and fulminant viral hepatitis in the industrialized world is 
constantly decreasing, drug-induced liver injury nowadays represents a major cause of 
acute liver failure (ALF). In developed countries, drug-induced liver injury accounts for 
nearly 2–5% of hospital admissions for jaundice, and for more than 50% of cases of ALF, 
with a significant number of patients undergoing a lethal course unless eligible for liver 
transplantation [1, 2]. In the pathogenesis of drug-induced hepatotoxicity, cell death is a 
crucial event leading to several clinical manifestations [2, 3]. A key feature of most drugs 
causing ALF is the production of toxic metabolites that either elicit an immune reaction 
or directly affect cell signaling in hepatocytes and cholangiocytes [3]. In humans, 
drug-induced liver injury can provoke almost all manifestations of acute and chronic liver 
disease. Most cases of drug-induced hepatotoxicity present histological features of 
hepatocellular damage, cholestasis and/or steatosis. Infrequently, a granulomatous 
reaction may be encountered [4]. 
In a minority of individuals receiving drugs, unpredictable adverse drug reactions 
occur which, in the absence of allergic symptoms (e.g. rash, eosinophilia, ANA or LKM) 
are presumed to be idiosyncratic events. Idiosyncratic reactions can even occur after an 
intermediate to protracted latency for more than 5–90 days and may exhibit a 
dose-related toxicity in rare susceptible individuals [5]. In addition, certain drugs inhibit 
mitochondrial functions, e.g. β-oxidation, which leads to free fatty acid (FFA) 
accumulation within the hepatocytes. Consequently, this results in steatosis and cell death 
with liver failure [6]. Indeed, it has recently been described that propofol 
(2,6-diisopropylphenol), an alkylphenol derivative which has sedative as well as hypnotic 
characteristics, can influence mitochondrial functions [7–9]. Pharmacokinetics of 
propofol follow a three compartment linear model: it presents with a fast distribution to 
tissues, a rapid metabolic clearance and a slow return to the circulation [8]. In this report 
we present the clinical course of a case of propofol-induced ALF, review the current 
literature and discuss its clinical relevance, underlying molecular and pharmacogenetic 
mechanisms and potential therapeutic options. 
Case Report 
A 35-year-old Caucasian woman, who underwent anesthesia with a total dose of 540 mg of propofol 
for the stripping of varicose veins of the right leg, was admitted to our hospital with the clinical 
diagnosis of ALF. One week after surgery, four- to sixfold elevated transaminases were documented for 
the first time. After hospital admission a liver biopsy was performed due to elevated liver enzymes, 
impaired coagulation and progredient jaundice (fig. 1). Histologic findings revealed florid and lobar 
accentuated as well as chronically persistent hepatitis with hepatocyte death, hepatocellular cholestasis 
and microvesicular fatty degeneration of 90% of the liver parenchyma (fig. 2a). These findings were 
consistent with the diagnosis of toxic liver damage, most likely caused by propofol. Because of the 
continuously elevated transaminases, bilirubin, INR and encephalopathy the patient was referred to the 
liver transplant centre of the University of Essen for transplant evaluation. 
Medical history was uneventful and earlier laboratory tests had always been in within normal limits. 
She had undergone hepatitis A and B vaccination years before, and there was no history of any 
medications or herbal drugs during three months before the event. Alcohol consumption was denied. 
Family history was unremarkable and there was no history of recent traveling. The serology for 
hepatotropic viruses (HAV, HBV, HCV, HIV, EBV, HSV and CMV) was negative. Laboratory tests for 
autoimmune markers (ANA, ANCA, LKM, SMA) and other entities such as Wilson’s disease or 
Budd-Chiari syndrome revealed no abnormalities. Compound heterozygosity was found while testing 
for hemochromatosis. Furthermore, initial liver biopsy did not show any pre-existing chronic liver cell 
damage.  
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Ultrasound revealed hepatomegaly and an inhomogeneous parenchyma without splenomegaly. The 
hepatic vasculature appeared regular. Perihepatic and hypogastric ascites was found. Upper endoscopy 
was performed to rule out esophageal varices. Transient elastography (FibroScan, Echosens, Paris, 
France) revealed liver stiffness, consistent with characteristic alterations in liver stiffness in patients 
diagnosed with ALF (own unpublished data) (fig. 3). As her mental status was stable, we continued the 
basic transplant evaluation. 
As combination therapy with corticosteroids and ursodeoxycholic acid has been shown to be a safe 
and efficient treatment for nonalcoholic toxic liver failure [10], therapy with 250 mg prednisolone 
per diem intravenously was started. The dose was subsequently tapered off to 40 mg per diem. During 
the course of treatment the patient’s condition improved rapidly. AST, ALT and bilirubin decreased to 
slightly elevated levels and INR levels remained stable (fig. 1). Thirty days after admission the clinical 
situation was significantly improved, encephalopathy and icterus had resolved and the patient was 
discharged. Six months later, a second biopsy was performed, which revealed only minimal bridging 
fibrosis and less steatosis as well as minimal periportal hepatitis (fig. 2b). 
To investigate the potential impact of genetic alterations in metabolizing enzymes on the clinical 
course we sequenced the genes of UDP-glycosyltransferase 1 family, polypeptide A9 (UGT1A9) and 
cytochrome P450, subfamily IIB, polypeptide 6 (CYP2B6), which catalyze the initial metabolizing step of 
propofol inactivation and excretion [11, 12]. Sequencing was performed as previously described [13–
15]. Analysis revealed a heterozygous *1a/*1c genotype for UGT1A9 (http://www.ugtalleles.ulaval.ca) as 
well as a heterozygous variant-genotype *1J/*5A for CYP2B6 (http://www.cypalleles.ki.se).  
One year after first admission the patient presented in good healthy condition, with liver enzymes, 
bilirubin and INR within normal ranges. Although ultrasound did not show any signs of portal 
hypertension, liver parenchyma was still inhomogeneous. Liver stiffness measured by transient 
elastography had decreased to 7.9 kPa. The patient still received a therapy with low-dose corticosteroids 
as an increase in transaminase levels was noted when corticosteroid administration was tapered off 
completely. 
Discussion 
Drug toxicity is often classified as intrinsic versus idiosyncratic. Intrinsic toxicity is 
dose-dependent, reproducible in animal models and occurs in every individual that is 
exposed to a sufficient dose of a certain drug. In contrast, idiosyncratic reactions are 
unpredictable and caused by the inability of single individuals to tolerate a given 
compound. They can manifest as hypersensitivity reactions accompanied by clinical 
symptoms such as fever, rash, and/or eosinophilia. Another type of idiosyncratic reaction 
is attributable to pharmacogenetic differences between individuals, i.e. genetic 
polymorphisms in the metabolism of certain substances [4]. 
Although 2,6-diisopropylphenol (propofol) is commonly used for sedation and 
introduction and/or maintenance of anesthesia, this is the first case report describing ALF 
due to propofol [9]. In the literature, there are three cases of acute hepatitis after brief 
sedation with propofol reported so far (table 1) [16–18]. 
As a matter of fact, histological findings in our case included extensive hepatocyte 
necrosis as well as fatty degeneration of 90% of the lobar parenchyma. However, there 
have been reports of hepatocellular injury related to sedation with propofol in intensive 
care units, particularly in children [7, 19, 20]. Parke et al. reported five cases of children 
who had been sedated with propofol and developed respiratory failure, metabolic acidosis 
and died in the end by refractory bradyarrhythmia in spite of critical care management. 
Postmortem examination of the liver performed in three of the five children revealed 
massive fatty degeneration [20]. Propofol infusion syndrome (PRIS), which is 
characterized by metabolic acidosis, lipemic plasma and myocardial failure, has been 
described in the literature [9]. In addition, hyperkalemia, hepatomegaly and 
rhabdomyolysis are key features of PRIS [21]. ALF, however, has not yet been described  
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in this context. Development of PRIS has mainly been reported in patients undergoing 
long-term sedation with propofol, but also during anesthesia of not more than five hours 
duration [9, 22, 23]. Although our patient does not match the criteria for PRIS, she 
developed a massive fatty liver. By excluding other known causes for this condition, it is 
to be suspected that there is a an actual causality between the use of propofol and ALF 
[24]. 
As to the proposed mechanisms of propofol-induced liver injury, it has been assumed 
that propofol-induced disturbance of the mitochondrial respiratory chain, which in 
consequence leads to insufficient cellular energy supply and consecutive cell death, might 
be the cause of PRIS [25, 26]. Indeed, in animal models propofol causes relevant damage 
to the mitochondria [27]. Furthermore, it has been described that propofol affects the 
generation and/or the maintenance of the transmembrane electrical potential [27] and 
impairs the electron flow along the mitochondrial electron chain [28]. In humans, 
propofol is believed to affect fatty acid oxidation by inducing an increase in 
malonylcarnitine, which leads to an inhibition of carnitine palmityl transferase 1, a 
mitochondrial transport protein for long-chain fatty acids [29]. Wolf et al. described a 
secondary inhibition of the respiratory chain at complex II [29]. In summary, entrance 
and utilization of FFAs is impaired [25]. Moreover, reduced cytochrome C oxidase 
activity in the presence of propofol has also been reported [7, 22]. Recently, Ypsilantis et 
al. described serious liver damage with focal hepatocyte necrosis and cholangitis in 
addition to low-grade hepatitis and steatosis in propofol-sedated rabbits during 
prolonged mechanical ventilation [19]. In addition, it is well known that certain drugs 
inhibit mitochondrial functions and, by rendering the pathway of β-oxidation inefficient, 
cause an accumulation of FFAs within the hepatocytes which culminates in steatosis [6]. 
Intriguingly, recent studies suggest that such intracellular FFA accumulation promotes 
death receptor expression, which leads to a reactive increase in the hepatocytes’ 
susceptibility to apoptosis and/or necrosis and, thereby, significantly promotes liver 
injury [30, 31]. 
Glucuronidation of propofol in the liver is the main pathway of its metabolism [32]. 
The glucuronidation of propofol is catalyzed by UGT1A9 [11]. Another important 
pathway is the oxidation of propofol to 4-hydroxy-propofol, by enzymes of the 
cytochrome P-450 family [33] It has been shown that CYP2B6 is the predominant 
isoform involved in the oxidation of propofol in human liver microsomes [34, 35]. In 
addition to that CYP2B6 is believed to be the principal determinant of interindividual 
variability in the hydroxylation of propofol by human liver microsomes [12]. For both 
enzymes it is well known that genetic variations can lead to clinically relevant alterations 
of propofol metabolism [36, 37]. Therefore, we decided to perform further examinations 
concerning genetic polymorphisms in our patient with regard to the enzymes mentioned 
above. Sequencing of UGT1A9 revealed a homozygous wild-type genotype of the coding 
region and two heterozygous single nucleotide polymorphisms in the regulatory 
promoter region, corresponding to a *1a/*1c diplotype. It has been shown that these 
promoter polymorphisms did not influence the amount of UGT1A9 on the protein level 
[38]. The patient carries the heterozygous CYP2B6 variant genotype *1J/*5A. 
Heterozygous CYP2B6 *5 allele carriers showed a significantly decreased expression and 
activity of CYP2B6 [15]. However, these results could not be confirmed for heterozygous 
*5 allele carriers in a second study, but this was possibly due to small sample size [14]. 
Therefore, an impact of this variant on the clinical course cannot be excluded, but it is 
very likely that the patient carries variants in other genes (e.g. in β-oxidation-related 
genes) contributing to the fulminant course of this adverse drug reaction (fig. 4).  
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With regard to our observations it might be reasonable to keep in mind that there are 
few cases of liver complications after administration of propofol. These are most probably 
due to idiosyncratic drug reactions. Patients treated with propofol should be monitored 
closely and if there are signs of hepatitis or ALF an idiosyncratic drug reaction should be 
considered as possible cause after other causes have been excluded. 
 
 
 
Table 1. Cases of acute hepatitis after brief sedation with propofol reported in the literature 
Paper Patient’s 
sex, age 
Total dose of 
propofol 
Laboratory analysis    Liver biopsy    Outcome 
Anand 
et al. [18] 
female 
17 
682 mg 
for femoral 
hernia repair 
ALT 1,567 U/l, 
AST 423 U/l 
  not performed    AST 20 U/l, 
ALT 62 U/l  
10 days later 
Polo- 
Romero 
et al. [17] 
male 
66 
brief sedation 
for therapeutic 
ERCP 
AST and ALT Ĺ 50 times 
the reference value, slight 
increase in GGT, AP, 
total bilirubin 8.9 mg/dl 
  not performed    2 months follow-up: 
patient was 
asymptomatic, liver 
enzymes were normal
Nguyen and 
Borum [16] 
female 
62 
250 mg 
for colonoscopy 
AST 2,309 U/l, 
ALT 1,313 U/l, 
AP 322 U/l, 
total bilirubin 4.8 mg/dl 
 hepatitis  with  severe 
activity and mild to 
focally moderate 
fibrosis 
 normalization  of 
transaminases in 
outpatient laboratory 
testing 
 
 
 
 
Fig. 1. a Course of ALT and AST. b Course of bilirubin. 
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Fig. 2. Liver histology (HE staining). a Before therapy. b After therapy. 
 
 
 
Fig. 3. Elastography of the liver (Fibroscan). 
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Fig. 4. Possible pathomechanism of Propofol-induced liver failure. N = Nucleus; FFA = free fatty 
acids. 
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